MTOR and adrenal cortex carcinoma: Proteasome inhibitors (12, 38), CDK inhibitors (38, 39), IGFR1 inhibitors (40, 41) and mTOR inhibitors (41, 42) have been reported to be effective in preclinical models of ACC, supporting the validity of our screen.